Every 424B that China SXT Pharmaceuticals, Inc. (SXTC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow SXTC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SXTC filings page.
China SXT Pharmaceuticals, Inc. is offering up to 8,000,000 Units at $1.50 each and registering up to 72,000,000 Class A Ordinary Shares underlying 8,000,000 Ordinary Warrants. Each Unit includes one Class A Ordinary Share or one Pre-Funded Warrant in its place, plus one Ordinary Warrant. The Over-Allotment Option covers up to 8,000,000 additional Units and up to 72,000,000 additional underlying shares; investors may acquire up to $12,000,000 of securities on the same terms during the 30-day period after closing. China SXT estimates net proceeds of approximately $11.06 million for working capital and general corporate purposes.
Ordinary Warrants are immediately exercisable at an initial $2.75 per share and expire on the one-year anniversary of the initial exercise date. They permit cashless exercise under specified circumstances and zero-price exercise when the Low Price is below the exercise price. If the Low Price equals the $0.50 Floor Price and all base warrants use zero-price exercise, up to 72,000,000 Class A Ordinary Shares could be issued; China SXT does not expect cash proceeds from warrant exercises.
China SXT is a British Virgin Islands holding company conducting its China business through subsidiaries and a variable interest entity under contractual arrangements. It says the VIE agreements have not been tested in a Chinese court and PRC regulatory uncertainty could affect its operations and U.S. listing.
China SXT Pharmaceuticals Inc. is conducting a primary offering of up to 4,500,000 Units, each consisting of one Class A Ordinary Share and one Ordinary Warrant, at $2.00 per Unit, for aggregate gross proceeds of up to $9,000,000. The company is also registering up to 63,000,000 Class A Ordinary Shares issuable upon exercise of the 4,500,000 Ordinary Warrants, which carry a $3.20 initial exercise price, cashless exercise, and a “zero price exercise” feature tied to VWAP and a $0.40 Floor Price.
The company expects to receive approximately $8.28 million in net proceeds after placement fees and expenses, to be used for working capital and general corporate purposes. A 7.0% cash fee will be paid to Univest Securities, LLC as placement agent. There is no minimum offering amount and no escrow arrangement.
Class A Ordinary Shares outstanding were 38,218,077 before the offering and are projected to reach 105,718,077 assuming full issuance of Units and zero price exercise of all Warrants, implying substantial potential dilution. The company highlights legal and operational risks from its China-based VIE structure and evolving PRC and U.S. regulations, including the HFCAA.
China SXT Pharmaceuticals, Inc. is offering up to $100,000,000 of Class A Ordinary Shares in an at-the-market offering under a Sales Agreement with Univest Securities, LLC dated June 1, 2026. The shares may be sold from time to time at market prices through Univest as agent or principal.
The Sales Agreement pays Univest a 3.0% commission and treats Univest as an underwriter for Securities Act purposes; the offering proceeds are to be used for general corporate purposes. As of May 29, 2026, there were 38,218,077 Class A Ordinary Shares outstanding.
China SXT Pharmaceuticals, Inc. is offering 2,000,000 Class A Ordinary Shares directly to investors at $0.38 per share pursuant to a Securities Purchase Agreement dated April 7, 2026, for gross proceeds of $760,000. The company will use net proceeds for working capital, development and commercialization of projects, and general corporate purposes.
The company is a BVI holding company that conducts operations through PRC subsidiaries and a VIE, which the prospectus highlights as a material risk because VIE agreements have not been court-tested in China. The filing reiterates risks from PRC regulatory change and HFCAA-related inspection uncertainty, states current auditor inspection status, and shows Class A shares listed on Nasdaq under "SXTC."
China SXT Pharmaceuticals is raising capital through a registered offering of 12,000,000 Class A Ordinary Shares at $0.15 per share, along with Pre-Funded Warrants to purchase up to 54,666,666 Class A Ordinary Shares at a purchase price of $0.149 and exercise price of $0.001 per share. The company is also registering 54,666,666 Class A Ordinary Shares issuable upon exercise of these Pre-Funded Warrants.
Total gross proceeds are expected to be about $9.95 million, with proceeds before expenses of about $9.25 million and an estimated net of approximately $9.11 million, to be used primarily for working capital and general corporate purposes. Shares outstanding would increase from 116,027,226 to 182,693,892 Class A Ordinary Shares if all Pre-Funded Warrants are exercised.
The company is a British Virgin Islands holding company operating in China through subsidiaries and a variable interest entity, and highlights significant regulatory and structural risks related to PRC oversight, its VIE arrangements, and potential U.S. trading limitations under the Holding Foreign Companies Accountable Act.